Another representative user was Rich, who was starting his fifth month on Wegovy and told us that he had lost five pounds so far, and that the side effects were minimal to nonexistent. The approval of semaglutide as a weight loss drug intersects in complex ways with the rise of telemedicine
Gigliotti contrasts such a patient with a person who has a BMI of 40 and diagnoses of hypertension, type 2 diabetes, CVD, and musculoskeletal issues, who may benefit from lifelong use of weight management medications
Include leptin-deficient cohorts if mechanistic generalizability is a goal
So youre potentially adding a drug that slows gastric emptying to a body that already has a predisposition to gastric dysmotility
But the GLP-1 boom has created an opportunity for compounders that has transformed pockets of the industry, with compounding pharmacies producing off-brand duplicates for likely millions of patients
LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus: From Discovery to Clinical Proof of Concept